Pfizer Closing the Gaps within Intestinal Ultrasound RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Tuesday 24th, September 2024
External Deadline: Tuesday 1st, October 2024
Description
The International Bowel Ultrasound Group (IBUS) is a non-profit association dedicated to research, training, and cooperation in the field of bowel diseases and intestinal ultrasound. Our mission is to improve patient care by promoting all efforts that enhance the diagnosis, treatment, and management of IBD.
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
For all research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
Date RFP Issued: August 22, 2024
Geographic Scope: Global (Applicants must be IBUS Members)
Clinical Area: Inflammatory Bowel Disease and Intestinal Ultrasound
Link to full RFP: Closing the Gaps within Intestinal Ultrasound
Application Due Date: October 1, 2024
Specific Area of Interest: The IBUS-Pfizer GMG collaboration invites proposals for research projects that address the following priority areas within the field of intestinal ultrasound (IUS) in inflammatory bowel disease (IBD):
- 1. IUS in Monitoring IBD: Proposals should focus on the broader role of IUS in monitoring various aspects of IBD, including disease activity, treatment response (including, but not limited to, Etrasimod), and complications. The primary outcome should be IUS-based findings, and the study design should allow for a multi-center approach.
- 2. Perianal IUS in Proctitis: Proposals should investigate the impact of perianal IUS on monitoring proctitis across various treatment modalities (including but not limited to Etrasimod). Multi-center studies are encouraged to provide a comprehensive understanding of this under-researched area.
- 3. IUS in Special Populations: Proposals should explore the utility of IUS in monitoring ulcerative colitis and Crohn’s disease in pregnant women, adolescents, and children. This area represents a significant gap in our knowledge and has the potential to improve care for these specific patient populations.
- 4. IUS Education: Proposals should investigate strategies for enhancing IUS competency development among healthcare professionals. This may include research on curriculum development (perianal, pediatric, advanced IUS, train-the-trainer), standardization of techniques (contrast-enhanced ultrasound, elastography), and evaluation of different learning modalities.
- 5. IUS in monitoring treatment with Etrasimod in a real-world setting: The use of IUS in monitoring the effectiveness of Etrasimod in UC.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com) or to office@bowel-ultrasound.org at IBUS.